Clinical Trial Update: Extracellular Matrix Marker of Arrhythmia Risk (EMMA)

View source ↗

Summary

Clinical trial update reporting results of the Extracellular Matrix Marker of Arrhythmia Risk (EMMA) study; the trial in cardiomyopathy and myocardial ischemia …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Arrhythmia
• Cardiomyopathy
• Myocardial Ischemia
• Sudden Cardiac Death

Snippet

Sponsor: Thomas Jefferson University | Conditions: Myocardiopathies, Ischemia, Myocardial | Status: COMPLETED | Results posted: 2014-06-04